{"transactions":[{"id":1144701,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T16:13:51.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013423","document":"form4-05162025_080547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588925013423/form4-05162025_080547.xml","form_type":"4"}},{"id":1486976,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T22:00:14.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.9,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-016056","document":"form4-06072024_060610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588924016056/form4-06072024_060610.xml","form_type":"4"}},{"id":1510365,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-17T16:13:27.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":42.69,"expiration_date":"2034-05-14","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-24-013476","document":"form4-05172024_080515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588924013476/form4-05172024_080515.xml","form_type":"4"}},{"id":1561648,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-25","kind":"sale","planned":false,"acquired":false,"shares":340000,"price":40.5,"value":13770000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2793987,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1561647,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-22","kind":"sale","planned":false,"acquired":false,"shares":413450,"price":40.51,"value":16748859.5,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3133987,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1561646,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":13718,"price":46.18,"value":633497.24,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3547437,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1561645,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":12617,"price":45.52,"value":574325.84,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.06 to $45.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3561155,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1561644,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":21918,"price":44,"value":964392.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3573772,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1561643,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-25T21:46:11.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":32756,"price":43,"value":1408508.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the \"Purchase\") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. (\"SVP X\"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by SVP X. Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3595690,"source":{"system":"sec-edgar","filing":"0001104659-24-038589","document":"tm249771-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924038589/tm249771-1_4seq1.xml","form_type":"4"}},{"id":1614469,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-27T16:47:24.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":22.72,"expiration_date":"2033-11-16","underlying":"Common Stock","underlying_shares":18235},"source":{"system":"sec-edgar","filing":"0001415889-24-005511","document":"form4-02272024_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588924005511/form4-02272024_090205.xml","form_type":"4"}},{"id":1614468,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T16:47:24.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1209764,"price":62.5,"value":75610250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\").  At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. (\"SM XI LLC\"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-005511","document":"form4-02272024_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588924005511/form4-02272024_090205.xml","form_type":"4"}},{"id":1614467,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T16:47:24.000Z","date":"2024-02-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1209764,"price":62.5,"value":75610250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 25, 2023, by and among RayzeBio, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\").  At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-005511","document":"form4-02272024_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588924005511/form4-02272024_090205.xml","form_type":"4"}},{"id":1663689,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-01T17:58:54.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":161290,"price":31,"value":4999990.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3628446,"source":{"system":"sec-edgar","filing":"0001104659-24-009537","document":"tm244970-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000110465924009537/tm244970-1_4seq1.xml","form_type":"4"}},{"id":1688031,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T23:00:21.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":3519,"price":13.49,"value":47471.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024."}],"balance_after":3519,"derivative":{"exercise_price":21.81,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":3519},"source":{"system":"sec-edgar","filing":"0001415889-24-000704","document":"form4-01042024_060107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588924000704/form4-01042024_060107.xml","form_type":"4"}},{"id":1735981,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-11-17T18:37:06.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":18235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board through such vesting date."}],"balance_after":18235,"derivative":{"exercise_price":22.72,"expiration_date":"2033-11-16","underlying":"Common Stock","underlying_shares":18235},"source":{"system":"sec-edgar","filing":"0001628280-23-039536","document":"wk-form4_1700264215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000162828023039536/wk-form4_1700264215.xml","form_type":"4"}},{"id":1775237,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":973653,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. (\"SM XI LLC\"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":973653},"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1775236,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":973653,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sofinnova Venture Partners X, L.P. (\"SVP X\").  Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":973653},"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1775235,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":236111,"price":18,"value":4249998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. (\"SM XI LLC\"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":1209764,"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1775234,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":236111,"price":18,"value":4249998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sofinnova Venture Partners X, L.P. (\"SVP X\").  Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":1209764,"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1775233,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":973653,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. (\"SM XI LLC\"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":973653,"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1775232,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T17:10:06.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":973653,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Every 5.141 shares of Series D Convertible Preferred Stock (the \"Preferred Stock\") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Sofinnova Venture Partners X, L.P. (\"SVP X\").  Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":973653,"source":{"system":"sec-edgar","filing":"0001209191-23-050305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123050305/doc4.xml","form_type":"4"}},{"id":1862519,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T22:00:34.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":16.3,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-23-009446","document":"form4-06082023_060612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588923009446/form4-06082023_060612.xml","form_type":"4"}},{"id":1894645,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-12T16:14:21.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":20000,"derivative":{"exercise_price":7.7,"expiration_date":"2033-05-09","underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-029024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919123029024/doc4.xml","form_type":"4"}},{"id":1989977,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":6073949,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Dr. Healy and Dr. Katabi are the managing member of SM X LLC and may be deemed to have shared voting and dispositive power over the shares held by SVP X. Each of Dr. Healy and Dr. Katabi disclaims beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989976,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"disposition_to_issuer","acquired":false,"shares":19608,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989975,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":9803,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."}],"balance_after":19608,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989974,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":6000,"price":14.32,"value":85920.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.30 to $14.35 inclusive. Dr. Healy undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Synergy Master Fund, LP (the \"Synergy Fund\"). Sofinnova Synergy Fund GP, LLC (the \"Synergy Fund GP\"), the general partner of the Syngery Fund, may be deemed to have sole voting and dispositive power over such shares. Dr. Healy is a managing member of the Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by the Synergy Fund. Dr. Healy disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":2026334,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":5,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-08T18:29:55.000Z","date":"2023-02-06","kind":"purchase","acquired":true,"shares":285714,"price":7,"value":1999998.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3467156,"source":{"system":"sec-edgar","filing":"0001104659-23-014661","document":"tm235954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923014661/tm235954-1_4seq1.xml","form_type":"4"}},{"id":2062955,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T22:00:25.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":2627,"price":18.08,"value":47496.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2023, the second installment vesting on June 30, 2023, the third installment vesting on September 30, 2023, and the fourth installment vesting on December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2023, the second installment vesting on June 30, 2023, the third installment vesting on September 30, 2023, and the fourth installment vesting on December 31, 2023."}],"balance_after":2627,"derivative":{"exercise_price":27.03,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":2627},"source":{"system":"sec-edgar","filing":"0001415889-23-000553","document":"form4-01052023_050114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000141588923000553/form4-01052023_050114.xml","form_type":"4"}},{"id":2185266,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T15:46:23.000Z","date":"2022-08-11","kind":"purchase","acquired":true,"shares":500000,"price":30,"value":15000000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of such shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":6073949,"source":{"system":"sec-edgar","filing":"0001104659-22-091184","document":"tm2223413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000110465922091184/tm2223413-2_4seq1.xml","form_type":"4"}},{"id":2224250,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T21:00:43.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":12.26,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001493152-22-017512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222017512/ownership.xml","form_type":"4"}},{"id":2254844,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T16:11:19.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":9925,"derivative":{"exercise_price":16.14,"expiration_date":"2032-05-23","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0001209191-22-032176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919122032176/doc4.xml","form_type":"4"}},{"id":2397555,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-02-14T18:17:42.000Z","date":"2022-02-10","kind":"purchase","acquired":true,"shares":266666,"price":15,"value":3999990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Michael Powell, a Reporting Person on SVP X's prior Section 16 filings with respect to the Issuer, is no longer a managing member of SM X, and accordingly, is not a Reporting Person on this Form 4."}],"balance_after":3181442,"source":{"system":"sec-edgar","filing":"0001104659-22-023301","document":"tm226514d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465922023301/tm226514d1_form4.xml","form_type":"4"}},{"id":2435634,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":4275000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1257353},"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435633,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":13571428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3991596},"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435632,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":325000,"price":16,"value":5200000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5573949,"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435631,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":5248949,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5248949,"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2444270,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T22:15:29.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":7240,"price":6.56,"value":47494.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2022, the second installment vesting on June 30, 2022, the third installment vesting on September 30, 2022, and the fourth installment vesting on December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2022, the second installment vesting on June 30, 2022, the third installment vesting on September 30, 2022, and the fourth installment vesting on December 31, 2022."}],"balance_after":7240,"derivative":{"exercise_price":10.93,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":7240},"source":{"system":"sec-edgar","filing":"0001493152-22-000463","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000149315222000463/ownership.xml","form_type":"4"}},{"id":2641476,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-07-06T20:27:39.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":10565238,"ownership":{"direct":false,"nature":"By Sofinnova Venture Parnters X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3401544},"source":{"system":"sec-edgar","filing":"0001104659-21-089437","document":"tm2121485-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089437/tm2121485-3_4seq1.xml","form_type":"4"}},{"id":2641475,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T20:27:39.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":2467,"price":11.147,"value":27499.649,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021."}],"balance_after":2467,"derivative":{"exercise_price":19.41,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":2467},"source":{"system":"sec-edgar","filing":"0001104659-21-089437","document":"tm2121485-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089437/tm2121485-3_4seq1.xml","form_type":"4"}},{"id":2641474,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:27:39.000Z","date":"2021-07-02","kind":"purchase","acquired":true,"shares":357142,"price":14,"value":4999988.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein."}],"balance_after":3758686,"source":{"system":"sec-edgar","filing":"0001104659-21-089437","document":"tm2121485-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089437/tm2121485-3_4seq1.xml","form_type":"4"}},{"id":2641473,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:27:39.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":3401544,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein."}],"balance_after":3401544,"source":{"system":"sec-edgar","filing":"0001104659-21-089437","document":"tm2121485-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089437/tm2121485-3_4seq1.xml","form_type":"4"}},{"id":2647909,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T22:34:31.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments, with the first installment vesting on July 29, 2021."}],"balance_after":25000,"derivative":{"exercise_price":14,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-088384","document":"tm2121189-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088384/tm2121189-7_4seq1.xml","form_type":"4"}},{"id":2647908,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-07-01T22:34:31.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":8082190,"price":1.893,"value":15299585.67,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein."}],"balance_after":10565238,"derivative":{"underlying":"Common Stock","underlying_shares":2602112},"source":{"system":"sec-edgar","filing":"0001104659-21-088384","document":"tm2121189-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088384/tm2121189-7_4seq1.xml","form_type":"4"}},{"id":2647907,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-07-01T22:34:31.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":1164213,"price":1.893,"value":2203855.209,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein."}],"balance_after":2483048,"derivative":{"underlying":"Common Stock","underlying_shares":374825},"source":{"system":"sec-edgar","filing":"0001104659-21-088384","document":"tm2121189-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921088384/tm2121189-7_4seq1.xml","form_type":"4"}},{"id":2707103,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-05-18T20:17:11.000Z","date":"2021-05-18","kind":"exercise","acquired":false,"shares":2187504,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":2187504},"source":{"system":"sec-edgar","filing":"0001209191-21-033812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919121033812/doc4.xml","form_type":"4"}},{"id":2707102,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:17:11.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":727272,"price":11,"value":7999992.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein."}],"balance_after":2914776,"source":{"system":"sec-edgar","filing":"0001209191-21-033812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919121033812/doc4.xml","form_type":"4"}},{"id":2707101,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:17:11.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":2187504,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein."}],"balance_after":2187504,"source":{"system":"sec-edgar","filing":"0001209191-21-033812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919121033812/doc4.xml","form_type":"4"}},{"id":2709838,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-17T20:40:17.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders."}],"balance_after":9925,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0001209191-21-033347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000120919121033347/doc4.xml","form_type":"4"}},{"id":2871905,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1200228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1200228},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871904,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1104209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1104209},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871903,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":450000,"price":20,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2754437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871902,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1200228,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2304437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871901,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1104209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1104209,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":3074862,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":11888112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1590808},"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074861,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":437500,"price":16,"value":7000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2028308,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074860,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":1590808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1590808,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3095397,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":12643557,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":599988},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095396,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":18044028,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":856262},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095395,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":58823,"price":17,"value":999991.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1515073,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095394,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":599988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1456250,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095393,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":856262,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":856262,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}}]}